Received FDA Breakthrough Therapy Designation for AAV2-hAQP1Reported positive three-year data from the Phase 1 AQUAx study of AAV2-hAQP1 for the treatment of grade 2/3 late radiation-induced xerostomiaEntered into an asset purchase agreement with Johnson & Johnson* (J&J) to acquire all interests in botaretigene sparoparvovec (bota-vec) for the treatment of X-linked retinitis pigmentosa (XLRP)Strengthened balance sheet with $100 million financingLONDON and NEW YORK, May 14, 2026 (GLOBE NEWSWIRE) — MeiraGTx Holdings plc (Nasdaq: MGTX), a vertically integrated, clinical stage genetic medicines company, today announced financial and operational results for the first quarter ended March 31, 2026, and provided a corporate update. “Our achievements in the first few months of 2026 have materially strengthened MeiraGTx...

LEXINGTON, Mass., May 14, 2026 (GLOBE NEWSWIRE) — Keros Therapeutics, Inc. (“Keros” or the “Company”) (Nasdaq: KROS), a clinical-stage biopharmaceutical company focused on developing and commercializing novel therapeutics to treat a wide range of patients with disorders that are linked to dysfunctional signaling of the transforming growth factor-beta (“TGF-ß”) family of proteins, today reported financial results for the quarter ended March 31, 2026. “Continuing to progress our pipeline remains our top priority, setting the stage for future catalysts and growth opportunities,” said Jasbir S. Seehra, Ph.D., President and Chief Executive Officer. “In addition, we are excited that our partner, Takeda Pharmaceuticals U.S.A., Inc. (“Takeda”), plans to advance elritercept into a Phase 3 clinical trial to evaluate elritercept as a treatment...

MIAMI, May 14, 2026 (GLOBE NEWSWIRE) — UMeWorld Inc. (OTCID:UMEW) today announced its unaudited financial results for the second fiscal quarter ended March 31, 2026, reflecting accelerating commercial activity across its consumer wellness platform and continued advancement of Project Verdant, the Company’s sustainable aviation fuel (SAF) initiative. Revenue for the quarter reached $351,187, representing a 138% increase from $147,455 in the prior quarter, driven by expanding distributor activity and growing sales across U.S. and Asia-Pacific markets. Gross profit increased to $15,152 compared to $4,692 in the prior quarter, while net loss improved to $105,450 from $145,230 in Q1 FY2026. The quarter marked an important transition for the Company as initial platform development efforts began converting into commercial revenue growth....

Late-breaking abstract for BB-301 presented at the Muscular Dystrophy Association (MDA) Clinical and Scientific Conference in March demonstrated durable responses to low dose BB-301 at 12-months and 24-months post-treatment and further improvements in depth of response following treatment with high dose BB-301 at the 3-month post-treatment follow-up time-point, with both doses demonstrating disease modifying outcomesBB-301 Phase 1b/2a interim clinical study results selected for oral presentation at the 2026 American Society of Gene and Cell Therapy (ASGCT) Annual Meeting on May 15Advancement of Cohort 2 enrollment continues as Patient 1 and Patient 2 were both safely treated with high dose BB-301 in the ongoing Phase 1b/2a clinical study of BB-301; Benitec remains on track to provide updated interim clinical study results in 2H-2026The...

After successful completion of FDA Type C meeting, Clene expects to submit an NDA for CNM-Au8® under the accelerated approval pathway in the third quarter of 2026 In January 2026, Clene completed an oversubscribed registered direct offering totaling over $28 million, including an initial tranche of more than $6 million and two additional tranches totaling over $22 million tied to regulatory milestones In May 2026, Clene amended its existing $10 million convertible debt facility, extending maturity by six months to August 2027 and eliminating required monthly principal and interest payments before maturity In May 2026, Clene completed a $7 million underwritten registered direct offering with a single investorSALT LAKE CITY, May 14, 2026 (GLOBE NEWSWIRE) — Clene Inc. (Nasdaq: CLNN) (along with its subsidiaries, “Clene”) and its...

Cash Position Grows to $25.9 Million KANSAS CITY, Kan., May 14, 2026 (GLOBE NEWSWIRE) — Cingulate Inc. (NASDAQ: CING), a biopharmaceutical company utilizing its proprietary Precision Timed Release™ (PTR™) drug delivery platform to develop a pipeline of next-generation products, today reported financial results for the quarter ended March 31, 2026, and provided a corporate update. “Cingulate remains focused on disciplined execution in 2026 and we believe we are well positioned to bring our lead ADHD asset, CTx-1301, to market,” said Cingulate CEO Shane J. Schaffer. “We continue to engage constructively with the FDA on our new drug application while advancing commercial readiness and manufacturing capabilities, and believe our current resources provide an extended cash runway into 2027.” Strengthened Balance Sheet Cingulate...

Company re-affirms 2026 guidance and provides expectations for medium-term outlook for 2027 to 2029 MILWAUKEE, May 14, 2026 (GLOBE NEWSWIRE) — Fiserv, Inc. (NASDAQ: FISV), a leading global provider of payments and financial services technology solutions, will host its Investor Day today beginning at 9:00 a.m. ET. The event will feature presentations from Fiserv senior leadership and will focus on the company’s strategy and execution priorities, as well as outline its medium-term financial outlook. At the event, the company will focus on how disciplined execution of its One Fiserv action plan, with opportunities at the intersection of its Merchant and Financial Solutions businesses, are expected to drive a constant compounder financial profile. “Our businesses play a critical role across the financial ecosystem,” said Mike Lyons,...

Company plans to submit a Biologics License Application (BLA) for aglatimagene besadenovec (aglatimagene or CAN-2409) in localized, intermediate- to high-risk prostate cancer in Q4 2026 Announced purpose-built commercial partnership with EVERSANA® to support potential U.S. launch of aglatimagene in localized prostate cancer Company reported extended survival tail observed in trial of aglatimagene in advanced non-small cell lung cancer (NSCLC) patients with inadequate response to immune checkpoint inhibitors (ICI) Company to report extended follow-up data from the positive phase 3 clinical trial of aglatimagene in patients with localized, intermediate- to high-risk prostate cancer at the American Urological Association (AUA) 2026 Annual Meeting Plenary Program in May 2026 Company plans to initiate a pivotal phase 3 clinical trial of aglatimagene...

MONTREAL, May 14, 2026 (GLOBE NEWSWIRE) — Dynacor Group Inc. (TSX: DNG) (“Dynacor” or the “Corporation”) today announced its unaudited financial and operational results1 for the first quarter ended March 31, 2026. “We delivered a strong start to the year that tracks both our operational and expansion plans,” said Jean Martineau, President & CEO. “Operations maintained strong ore supply momentum, which, coupled with higher recoveries, resulted in record first-quarter production volumes. Supported by the higher gold pricing, this operational outperformance translated into record earnings per share and operating cash flow. With initial production from two new plants set to come online this year, including the first from Senegal later this quarter, we remain firmly on track to deliver stronger production in the second half of...

TORONTO, May 14, 2026 (GLOBE NEWSWIRE) — Electra Battery Materials Corporation (NASDAQ: ELBM; TSX-V: ELBM) (“Electra” or the “Company”) today filed its operating results for the three months ended March 31, 2026, including the completion of several milestones in the construction of North America’s first battery-grade cobalt sulfate refinery. During the quarter, Electra advanced several refinery construction activities, approved a comprehensive construction budget and execution schedule, strengthened its commercial position through a strategic supply agreement with LG Energy Solution, and enhanced financial flexibility through expanded capital markets initiatives and government support. “During the quarter, we executed several construction activities supported by disciplined capital management while maintaining a strong liquidity...